FSN Subsidiary Boosters Achieves Record April Results... "Net Profit Turnaround Expected This Year"

FSN, a KOSDAQ-listed company, announced on the 19th that its subsidiary Boosters continued its growth trajectory, achieving its highest-ever monthly performance as of April.

In April 2026, Boosters posted consolidated sales of 22.7 billion won and operating profit of 6.1 billion won. Compared to the same period last year, sales increased by approximately 3.2 billion won, and operating profit rose by 1.9 billion won. The growth rates were 16% and 46%, respectively.

The company explained that the record monthly performance was driven by the entry into the peak season, as well as balanced expansion in sales and profitability across partner brands, alongside continued growth in overseas sales, particularly in Japan.

Thanks to the growth of Boosters, FSN's financial structure is also rapidly improving. FSN recorded a net loss of 60.9 billion won in 2024 due to factors such as impairment of subsidiary value, but through business structure overhaul and management efficiency initiatives, the loss was reduced to 15.9 billion won last year. Net loss for the first quarter of this year also decreased to around 100 million won.

The company explained that most of the past losses were accounting losses involving no actual cash outflows, such as impairment losses on subsidiaries and derivative valuation losses incurred during the process of increasing corporate value. In addition, the reduction in value from the separation of consolidated subsidiaries last year and the one-off expenses in the first quarter of this year have already been reflected in the financial statements, thereby resolving a significant portion of potential risks.

Accordingly, the company anticipates a possible turnaround in net profit starting from the second quarter of this year, when Boosters' peak season performance is reflected.

FSN is also working to improve its existing business fundamentals and secure new growth drivers. The company reorganized its existing platform businesses, including Daedamo and Jeonghandak, into a 'Healthcare Platform Division.' With demand for overseas patients visiting Korea on the rise, FSN plans to focus on attracting international patients and developing new revenue models. According to the Ministry of Health and Welfare, the number of foreign patients visiting Korea exceeded 2 million last year.

An FSN representative stated, "Recently, the domestic stock market has been moving around specific sectors such as semiconductors and artificial intelligence (AI), resulting in our stock price being excessively undervalued relative to our earnings growth and intrinsic value," adding, "Rather than chasing short-term themes, we aim to be properly valued in the market based on our financial performance and asset value."

The spokesperson further emphasized, "As most of the accounting and one-off losses that have been a burden are now reflected, we will grow into a more stable company based on improved performance going forward."

This performance is drawing market attention as it reflects not only Boosters' robust growth, but also the visible normalization of FSN's finances and profitability improvement.

This content was produced with the assistance of AI translation services.